Prelude Therapeutics Inc (PRLD): Revenue

Annual figures by period end, from SEC filings.

$12.14M

Year ended 2025-12-31

$22.42M

Trailing 12 months to 2026-06-30

2024-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$12.14M	+73.4%	2026-03-10, From 2025-01-01
2024-12-31	$7.00M	n/a	2026-03-10, From 2024-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Prelude Therapeutics Inc (PRLD)	2025-12-31	$12.14M	+73.4%
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	$12.45M	-25.2%
Jaguar Health, Inc. (JAGX)	2025-12-31	$11.51M	-1.5%
Evommune, Inc. (EVMN)	2025-12-31	$13.00M	+85.7%
Tonix Pharmaceuticals Holding Corp. (TNXP)	2025-12-31	$13.11M	+29.8%
Palatin Technologies Inc (PTN)	2026-06-30	$13.19M	n/a
Crescent Biopharma, Inc. (CBIO)	2025-12-31	$10.84M	n/a
CV Sciences, Inc. (CVSI)	2025-12-31	$13.79M	-12.2%
Pyxis Oncology, Inc. (PYXS)	2025-12-31	$13.86M	-14.2%

Compare PRLD, EMMA, JAGX, EVMN side by side · Screen every company in Pharmaceutical Preparations ↗